PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15047028-6 2004 Noradrenaline overflow increased similarly to potassium depolarisation in vehicle and STZ-diabetic rats, whereas diabetic rats showed a significantly increased NPY overflow response to potassium depolarisation compared to vehicle rats. Potassium 185-194 neuropeptide Y Rattus norvegicus 160-163 18790060-0 2008 Neuropeptide Y activates a G-protein-coupled inwardly rectifying potassium current and dampens excitability in the lateral amygdala. Potassium 65-74 neuropeptide Y Rattus norvegicus 0-14 16040808-6 2005 Second, using physiological studies, we demonstrate that NPY specifically enhances an inwardly rectifying potassium current via NPY-Y1 receptors. Potassium 106-115 neuropeptide Y Rattus norvegicus 57-60 16040808-6 2005 Second, using physiological studies, we demonstrate that NPY specifically enhances an inwardly rectifying potassium current via NPY-Y1 receptors. Potassium 106-115 neuropeptide Y Rattus norvegicus 128-131 9247743-5 1997 18-month old animals showed a reduced ability to release both NPY and noradrenaline to a potassium depolarisation stimulus. Potassium 89-98 neuropeptide Y Rattus norvegicus 62-65 11934810-0 2002 Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Potassium 69-78 neuropeptide Y Rattus norvegicus 0-14 11934810-2 2002 The modulation of 4-aminopyridine sensitive transient outward potassium current (4-AP I(to)) by neuropeptide Y (NPY) (100 nM) in rat ventricular myocytes was examined using the whole cell voltage-clamp technique. Potassium 62-71 neuropeptide Y Rattus norvegicus 96-110 11934810-2 2002 The modulation of 4-aminopyridine sensitive transient outward potassium current (4-AP I(to)) by neuropeptide Y (NPY) (100 nM) in rat ventricular myocytes was examined using the whole cell voltage-clamp technique. Potassium 62-71 neuropeptide Y Rattus norvegicus 112-115 10704718-3 2000 However, the melanocortin-4 agonists, alpha-MSH and MT-II, significantly inhibited potassium-stimulated NPY release (p < 0.01) without significantly altering basal NPY release. Potassium 83-92 neuropeptide Y Rattus norvegicus 104-107 10444309-15 1999 NPY significantly stimulated SS and inhibited basal and potassium-stimulated GHRH release, while potentiating potassium-evoked AVP secretion. Potassium 56-65 neuropeptide Y Rattus norvegicus 0-3 10444309-15 1999 NPY significantly stimulated SS and inhibited basal and potassium-stimulated GHRH release, while potentiating potassium-evoked AVP secretion. Potassium 110-119 neuropeptide Y Rattus norvegicus 0-3 10986350-1 2000 Previous studies in our laboratory using rat brain tissue have shown that neuropeptide Y (NPY) can enhance NMDA- and potassium-stimulated dopamine release from various brain regions and that this enhancement is reversed by sigma (sigma) receptor antagonists. Potassium 117-126 neuropeptide Y Rattus norvegicus 74-88 10986350-1 2000 Previous studies in our laboratory using rat brain tissue have shown that neuropeptide Y (NPY) can enhance NMDA- and potassium-stimulated dopamine release from various brain regions and that this enhancement is reversed by sigma (sigma) receptor antagonists. Potassium 117-126 neuropeptide Y Rattus norvegicus 90-93 10428060-3 1999 High-potassium stimulation (60 mM) of the slices produced a calcium-dependent threefold increase in NPY release above basal release. Potassium 5-14 neuropeptide Y Rattus norvegicus 100-103 9751185-5 1998 NPY overflow from the rat PVN was increased threefold by perfusion of a depolarizing concentration of potassium (50 mmol/L KCl). Potassium 102-111 neuropeptide Y Rattus norvegicus 0-3 9507190-2 1998 During potassium-induced depolarisations, a 93% increase in extracellular levels of NPY was observed. Potassium 7-16 neuropeptide Y Rattus norvegicus 84-87 9263910-4 1997 NPY (0.1 microM) depolarized arterial smooth muscle cells from -55 to -47 mV and increased wall tension by 0.22 N m-1, representing 11% of the contraction elicited by a high-potassium solution. Potassium 174-183 neuropeptide Y Rattus norvegicus 0-3 9098556-0 1997 Neuropeptide Y and [Leu31,Pro34]neuropeptide Y potentiate potassium-induced noradrenaline release in the paraventricular nucleus of the aged rat. Potassium 58-67 neuropeptide Y Rattus norvegicus 0-14 9098556-0 1997 Neuropeptide Y and [Leu31,Pro34]neuropeptide Y potentiate potassium-induced noradrenaline release in the paraventricular nucleus of the aged rat. Potassium 58-67 neuropeptide Y Rattus norvegicus 32-46 9098556-1 1997 This microdialysis study investigated the effects of NPY and the Y1 selective agonist [Leu31, Pro34]NPY on basal and potassium-stimulated noradrenaline release in the PVN of 18-month-old anaesthetised male Sprague-Dawley rats. Potassium 117-126 neuropeptide Y Rattus norvegicus 100-103 9098556-7 1997 Thus, in 18-month-old animals with reduced endogenous hypothalamic NPY content, administration of NPY or [Leu31, Pro34]NPY increased potassium-induced noradrenaline release to levels seen in 3-month-old rats. Potassium 133-142 neuropeptide Y Rattus norvegicus 98-101 9098556-7 1997 Thus, in 18-month-old animals with reduced endogenous hypothalamic NPY content, administration of NPY or [Leu31, Pro34]NPY increased potassium-induced noradrenaline release to levels seen in 3-month-old rats. Potassium 133-142 neuropeptide Y Rattus norvegicus 98-101 8852815-8 1996 A concentration-dependent in vitro release of potassium from tissues of parotid and submandibular glands in response to NPY occurred and here, submandibular gland tissue was the most sensitive. Potassium 46-55 neuropeptide Y Rattus norvegicus 120-123 7582505-0 1995 The effect of neuropeptide Y on sodium, chloride and potassium transport across the rat distal colon. Potassium 53-62 neuropeptide Y Rattus norvegicus 14-28 7858862-0 1994 Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Potassium 24-33 neuropeptide Y Rattus norvegicus 0-14 2483949-11 1989 In contrast, 10(-7) M NPY contracted femoral veins by up to 68% relative to 60 mM potassium induced contraction, and there was no potentiation of alpha-adrenoceptor mediated contractions. Potassium 82-91 neuropeptide Y Rattus norvegicus 22-25 8137725-3 1994 NPY dose-dependently potentiated vasopressin release evoked by high extracellular potassium (56 mM), with a maximal enhancement of 223% (10(-7) M NPY). Potassium 82-91 neuropeptide Y Rattus norvegicus 0-3 8413845-5 1993 Prazosin decreased both the basal and potassium-evoked release of NPY. Potassium 38-47 neuropeptide Y Rattus norvegicus 66-69 8413845-6 1993 Propranolol had the most profound effect on release of NPY, causing a significant decrease in basal release and a large decrease in the potassium-evoked release of NPY from slices of hypothalamus. Potassium 136-145 neuropeptide Y Rattus norvegicus 55-58 8413845-6 1993 Propranolol had the most profound effect on release of NPY, causing a significant decrease in basal release and a large decrease in the potassium-evoked release of NPY from slices of hypothalamus. Potassium 136-145 neuropeptide Y Rattus norvegicus 164-167 8327072-10 1993 The potassium perfusion produced an increase in the release of neuropeptide Y (peak at 71.4 +/- 7.1 pg/tube; p < 0.01), and this phenomenon was reproduced with the second potassium stimulation (peak at 47.7 +/- 2.3 vs pg/tube; p < 0.05). Potassium 4-13 neuropeptide Y Rattus norvegicus 63-77 8327072-10 1993 The potassium perfusion produced an increase in the release of neuropeptide Y (peak at 71.4 +/- 7.1 pg/tube; p < 0.01), and this phenomenon was reproduced with the second potassium stimulation (peak at 47.7 +/- 2.3 vs pg/tube; p < 0.05). Potassium 174-183 neuropeptide Y Rattus norvegicus 63-77 1715087-9 1991 In contrast, NPY (10(-6) M) produced significant inhibition of amylase release from pancreatic lobules that had been stimulated by 75 mM potassium (135 +/- 11% versus 177 +/- 18% of basal level) or by 25 microM veratridine (196 +/- 19% versus 398 +/- 152%). Potassium 137-146 neuropeptide Y Rattus norvegicus 13-16 8189249-3 1994 At the presynaptic level, neuropeptide Y inhibits by 45%, with an EC50 of 50 nM, the potassium-evoked noradrenaline release from pineal nerve endings. Potassium 85-94 neuropeptide Y Rattus norvegicus 26-40 30971438-3 2019 [ahx5-24]NPY also reduced tonic activation of GABAB receptors (GABABR), which increased PN excitability through inhibition of a tonic, inwardly rectifying potassium current (KIR ). Potassium 155-164 neuropeptide Y Rattus norvegicus 9-12 2754431-0 1989 Neuropeptide Y increases the inhibitory effects of clonidine on potassium evoked 3H-noradrenaline but not 3H-5-hydroxytryptamine release from synaptosomes of the hypothalamus and the frontoparietal cortex of the male Sprague-Dawley rat. Potassium 64-73 neuropeptide Y Rattus norvegicus 0-14 2850631-5 1988 NPY was also seen to decrease the potassium-induced release of norepinephrine (NE) from slices obtained from the posterior hypothalamic nucleus. Potassium 34-43 neuropeptide Y Rattus norvegicus 0-3